medigraphic.com
ISSN 1995-9427 (Print)

2021, Number 3

<< Back Next >>

Invest Medicoquir 2021; 13 (3)

Inflammation indices as predictors of lung damage in recovered COVID-19 patients

Reyes EL, Lage DA, Macías AC

Language: Spanish
References: 33
Page: 1-19
PDF size: 222.56 Kb.


ABSTRACT

Introduction. The 2019 new coronavirus (COVID-19) pandemic has affected more than 40 million people around the world. The acute phase of the disease has been widely described, however, there are few studies in the recovery phase. A third of recovered patients are left with inflammatory lung lesions that can lead to irreversible fibrosis. The present study evaluates three inflammation markers in recovered COVID-19 patients with and without lung damage, as well as the effect of treatment on these markers. Methods. A prospective longitudinal pilot study was conducted in 49 recovered COVID-19 patients, 20 of them with lung damage and 29 without damage. A complete blood count was performed, obtaining the absolute count of neutrophils (N), lymphocytes (L) and platelets (P), for the analysis of the neutrophil/lymphocyte ratio (NLR), the platelet/lymphocyte ratio (PLR) and the index systemic immune inflammation (SII). Results. PLR and SII were increased in patients with lung damage. The PLR was the best index to predict the damage, levels greater than or equal to 112.07, it was associated with a 7-fold increase in risk. Treatment with prednisone decreased the PLR in patients recovered after one month of treatment. Conclusions. PLR and SII are predictive markers of lung damage, with PLR being the one that best discriminates between damaged patients. These results suggest that prednisone treatment could be used in recovered patients with lung damage and a PLR greater than or equal to 112.07.


REFERENCES

  1. COVID-19 Weekly Epidemiological Update. https://www.who.int/docs/default-source/coronaviruse/situation-reports/20201020-weekly-epi-update-10.pdf. Accessed October 21, 2020.

  2. Li K, Wu J, Wu F, Guo D, Chen L, et al. The Clinical and Chest CT Features Associated With Severe and Critical COVID-19 Pneumonia. Invest Radiol 2020;55: 00–00

  3. Zheng M, Gao Y, Wang G, Song G, Liu S, et al. Functional exhaustion of antiviral lymphocytes in COVID-19 patients. Cellular & Molecular Immunology 2020. https://doi.org/10.1038/s41423-020-0402-2

  4. Liu J, Li S, Liu J, Liang B, Wang X, et al. Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients. EBioMedicine 55 (2020) 102763. https://doi.org/10.1016/j.ebiom.2020.102763

  5. Fan Wang, Jiayan Nie, Haizhou Wang, Qiu Zhao, Yong Xiong, et al. Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia. JID 2020. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7184346/pdf/jiaa150.pdf

  6. Wan S, Yi Q, Fan Sh, Lv J, Zhang X, et al. Relationships among Lymphocyte Subsets, Cytokines, and the Pulmonary Inflammation Index in Coronavirus (COVID-19) Infected Patients. British Journal of Haematology 2020: 189,428–437. doi: 10.1111/bjh.16659

  7. Francesca Salamanna, Melania Maglio, Maria Paola Landini & Milena Fini. Platelet functions and activities as potential hematologic parameters related to Coronavirus Disease 2019 (Covid-19. Platelets 2020, 31:5, 627-632, DOI: 10.1080/09537104.2020.1762852

  8. Yanli Liu, Wenwu Sun, Yanan Guo, Liangkai Chen, Lijuan Zhang, et al. Association between platelet parameters and mortality in coronavirus disease 2019: Retrospective cohort study. Platelets 2020, DOI: 10.1080/09537104.2020.1754383

  9. Lolli C, Caffo O, Scarpi E, Aieta M, Conteduca V, Maines F et al. Systemic Immune-Inflammation Index Predicts the Clinical Outcome in Patients with mCRPC Treated with Abiraterone. Front. Pharmacol 2016; 7:376. doi: 10.3389/fphar.2016.00376

  10. Howard R, Kanetsky P.A, Egan K.M. Exploring the prognostic value of the neutrophil-to-lymphocyte ratio in cancer. Scientific Reports 2019; 9:19673. https://doi.org/10.1038/s41598-019-56218-z

  11. Takada T, et al. Added value of inflammatory markers to vital signs to predict mortality in patients suspected of severe infection. American Journal of Emergency Medicine. 2019. https://doi.org/10.1016/j.ajem.2019.11.030

  12. Kucuk H, Tecer D, Goker B, et al. Platelet/lymphocyte ratio and mean platelet volume in patients with granulomatosis with polyangiitis. Advances in Rheumatology 2020; 60:4 https://doi.org/10.1186/s42358-019-0110-8

  13. Çetinkaya ÖA, Çelik SU, Terzioğlu SG, Eroğlu A. The Predictive Value of the Neutrophil-to-Lymphocyte and Platelet-toLymphocyte Ratio in Patients with Recurrent Idiopathic Granulomatous Mastitis. Eur J Breast Health 2020; 16(1): 61-65.

  14. Paliogiannis P, Fois A G, Sotgia S, et al. Neutrophil to lymphocyte ratio and clinical outcomes in COPD: recent evidence and future perspectives. Eur Respir Rev 2018; 27: 170113 [https://doi.org/10.1183/16000617.0113-2017]

  15. Palella E, Cimino R, Pullano S A, et al. Laboratory Parameters of Hemostasis, Adhesion Molecules, and Inflammation in Type 2 Diabetes Mellitus: Correlation with Glycemic Control. Int. J. Environ. Res. Public Health 2020, 17, 300; doi:10.3390/ijerph17010300

  16. Liu J, Liu Y, Xiang P, Pu L, Xiong H, et al. Neutrophil-to-Lymphocyte Ratio Predicts Severe Illness Patients with 2019 Novel Coronavirus in the Early Stage. 2020. https://doi.org/10.1101/2020.02.10.20021584

  17. Tao Chen, Di Wu, Huilong Chen, Weiming Yan, Danlei Yang, et al. Clinical characteristics of 113 deceased patients with coronavirus disease 2019: retrospective study. BMJ 2020; 368:m1091. http://dx.doi.org/10.1136/bmj.m1091

  18. Xiong Q, Xu M, Li J, Liu Y, Zhang J, Xu Y, Dong W, Clinical sequelae of COVID-19 survivors in Wuhan, China: a single-centre longitudinal study, Clinical Microbiology and Infection, https://doi.org/10.1016/j.cmi.2020.09.023.

  19. Liu BM, Yang QQ, Zhao LY, Xie W, Si XY (2020). Epidemiological characteristics of COVID-19 patients in convalescence period. Epidemiology and Infection 148, e108, 1–9. https://doi.org/10.1017/S0950268820001181

  20. Xuetao Cao. COVID-19: immunopathology and its implications for therapy. Nature reviews 2020. https://doi.org/10.1038/s41577-020-0308-3

  21. Geng Li, Yaohuao Fan, Yanni Lai, Tiantian Han, Zonghui Li, et al. Coronavirus Infections and Immune Responses. J Med Virol 2020; 92:424–432. doi: 10.1002/jmv.25685.

  22. Zhao G, Su Y, Sun X, et al. A comparative study of the laboratory features of COVID-19 and other viral pneumonias in the recovery stage. J Clin Lab Anal. 2020;00:e23483. https://doi.org/10.1002/jcla.23483

  23. Xu P, Zhou Q, Xu J. Mechanism of thrombocytopenia in COVID-19 patients. Ann Hematol. 2020;1–4.

  24. Middleton EA, Weyrich AS, Zimmerman GA. Platelets in pulmonary immune responses and inflammatory lung diseases. Physiol Rev 96: 1211–1259, 2016. Published August 3, 2016; doi:10.1152/physrev.00038.2015

  25. Germolec DR, Shipkowski KA, Frawley RP, Evans E. Markers of Inflammation. Immunotoxicity Testing: Methods and Protocols, Methods in Molecular Biology, 2018: 1803(5) 57-77. https://doi.org/10.1007/978-1-4939-8549-4_5

  26. Wang Q, Ma J, Jiang Z, Ming l. Prognostic value of neutrophil-to-lymphocyte ratio and platelet-to-lymphocyte ratio in acute pulmonary embolism: a systematic review and meta-analysis. Int Angiol 2018;37:4-11. DOI: 10.23736/S0392-9590.17.03848-2)

  27. Fabrizio Galimberti, Jeffrey McBride, Megan Cronin, Yumeng Li, Joshua Fox, et al. Evidence-based best practice advice for patients treated with systemic immunosuppressants in relation to COVID-19. Clinics in dermatology 2020. https://doi.org/10.1016/j.clindermatol.2020.05.003

  28. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am 2016; 42:157-176. ix-x.

  29. Xing X, Hu S, Chen M, et al. Severe acute respiratory infection risk following glucocorticosteroid treatment in uncomplicated influenza-like illness resulting from pH1N1 influenza infection: a case control study. BMC Infect Dis 2019;19, 1080.

  30. Stankus SJ, Dlugopolski M, Packer D. Management of Herpes zoster (shingles) and postherpetic neuralgia. Am Fam Physician 2000; 61:2437.

  31. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet Lond Engl 2020; 395:473-475.

  32. Shang L, Zhao J, Hu Y, et al. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet Lond Engl 2020; 395:683-684.

  33. Pan American Health Organization. Ongoing Living Update of Potential COVID-19 Therapeutics: Summary of Rapid Systematic Reviews. RAPID REVIEW, 22 September 2020. www.paho.org/coronavirus.




2020     |     www.medigraphic.com